Since December 2019, a pneumonia associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), named as coronavirus disease 2019 (COVID-19) by World Health Organization (WHO), emerged in Wuhan, China ([@r1][@r2]--[@r3]). The epidemic spread rapidly worldwide within 3 mo and was characterized as a pandemic by WHO on March 11, 2020. As of March 12, 2020, a total of 80,980 confirmed cases and 3,173 deaths had been reported in China. Meanwhile, a total of 44,377 confirmed cases and 1,446 deaths was reported in another 108 countries or regions. Currently, there are no approved specific antiviral agents targeting the novel virus, while some drugs are still under investigation, including remdesivir and lopinavir/ritonavir ([@r4], [@r5]). Although remdesivir was reported to possess potential antiviral effect in one COVID-19 patient from the United States, randomized controlled trials of this drug are ongoing to determine its safety and efficacy ([@r6]). Moreover, the corticosteroid treatment for COVID-19 lung injury remains controversial, due to delayed clearance of viral infection and complications ([@r7], [@r8]). Since the effective vaccine and specific antiviral medicines are unavailable, it is an urgent need to look for an alternative strategy for COVID-19 treatment, especially among severe patients.

Convalescent plasma (CP) therapy, a classic adaptive immunotherapy, has been applied to the prevention and treatment of many infectious diseases for more than one century. Over the past two decades, CP therapy was successfully used in the treatment of SARS, MERS, and 2009 H1N1 pandemic with satisfactory efficacy and safety ([@r9][@r10][@r11]--[@r12]). A meta-analysis from 32 studies of SARS coronavirus infection and severe influenza showed a statistically significant reduction in the pooled odds of mortality following CP therapy, compared with placebo or no therapy (odds ratio, 0.25; 95% confidence interval, 0.14--0.45) ([@r13]). However, the CP therapy was unable to significantly improve the survival in the Ebola virus disease, probably due to the absence of data of neutralizing antibody titration for stratified analysis ([@r14]). Since the virological and clinical characteristics share similarity among SARS, Middle East Respiratory Syndrome (MERS), and COVID-19 ([@r15]), CP therapy might be a promising treatment option for COVID-19 rescue ([@r16]). Patients who have recovered from COVID-19 with a high neutralizing antibody titer may be a valuable donor source of CP. Nevertheless, the potential clinical benefit and risk of convalescent blood products in COVID-19 remains uncertain. Hence, we performed this pilot study in three participating hospitals to explore the feasibility of CP treatment in 10 severe COVID-19 patients.

Results {#s1}
=======

Neutralizing Activity of CP against SARS-CoV-2. {#s2}
-----------------------------------------------

The neutralizing activity against SARS-CoV-2 was evaluated by classical plaque reduction test using a recently isolated viral strain ([@r1]). Among the first batch of CP samples from 40 recovered COVID-19 patients, 39 showed high antibody titers of at least 1:160, whereas only one had an antibody titer of 1:32. This result laid the basis for our pilot clinical trial using CP in severe patients.

General Characteristics of Patients in the Trial. {#s3}
-------------------------------------------------

From January 23, 2020, to February 19, 2020, 10 severe COVID-19 patients (six males and four females) were enrolled and received CP transfusion. The median age was 52.5 y (interquartile range \[IQR\], 45.0 y to 59.5 y) ([Table 1](#t01){ref-type="table"}). None of the patients had direct exposure to Huanan Seafood Wholesale Market. The median time from onset of symptoms to hospital admission and CP transfusion was 6 d (IQR, 2.5 d to 8.5 d) and 16.5 d (IQR, 11.0 d to 19.3 d), respectively. Three patients were affected by clustering infection. The most common symptoms at disease onset were fever (7 of 10 patients), cough (eight cases), and shortness of breath (eight cases), while less common symptoms included sputum production (five cases), chest pain (two cases), diarrhea (two cases), nausea and vomiting (two cases), headache (one case), and sore throat (one case). Four patients had underlying chronic diseases, including cardiovascular and/or cerebrovascular diseases and essential hypertension. Nine patients received arbidol monotherapy or combination therapy with remdesivir (in one case not included in the current clinical trial), or ribavirin, or peramivir, while one patient received ribavirin monotherapy ([Table 2](#t02){ref-type="table"}). Antibacterial or antifungal treatment was used when patients had coinfection. Six patients received intravenous (i.v.) methylprednisolone (20 mg every 24 h).

###### 

Clinical characteristics of patients receiving CP transfusion

  Patient no.   Sex   Age, y   Clinical classification   Days of admission from symptom onset   Days of CP therapy from symptom onset   Clustering infection   Principal symptoms                                                            Comorbidity
  ------------- ----- -------- ------------------------- -------------------------------------- --------------------------------------- ---------------------- ----------------------------------------------------------------------------- ---------------------------------------------
  1             M     46       Severe                    8                                      11                                      No                     Fever, cough, sputum production, shortness of breath, chest pain              Hypertension
  2             F     34       Severe                    0                                      11                                      Yes                    Cough, shortness of breath, chest pain, nausea and vomiting                   None
  3             M     42       Severe                    8                                      19                                      Yes                    Fever, cough, sputum production, shortness of breath, sore throat, diarrhea   Hypertension
  4             F     55       Severe                    10                                     19                                      No                     Fever, cough, sputum production, shortness of breath                          None
  5             M     57       Severe                    4                                      14                                      No                     Fever, shortness of breath                                                    None
  6             F     78       Severe                    8                                      17                                      Yes                    Fever, cough, sputum production, shortness of breath, muscle ache             None
  7             M     56       Severe                    4                                      16                                      No                     Fever, cough, sputum production, arthralgia                                   None
  8             M     67       Severe                    10                                     20                                      No                     Fever, cough, headache, diarrhea, vomiting                                    Cardiovascular and cerebrovascular diseases
  9             F     49       Severe                    1                                      10                                      No                     Cough, shortness of breath                                                    None
  10            M     50       Severe                    3                                      20                                      No                     Shortness of breath                                                           Hypertension

M, male; F, female.

###### 

Other treatments of ten patients receiving CP transfusion

                             Drugs administered                                Oxygen support                                                                                                               
  -------------------------- ------------------------------------------------- ------------------------------------------------ ------------------------- ------------------------------------------------- ---------------------------------------
  1                          Arbidol 0.2 g q8h po.Ribavirin 0.5 g qd i.v.      Cefoperazone Sodium i.v.                         None                      High-flow nasal cannula, mechanical ventilation   Mechanical ventilation
  2                          Arbidol 0.2 g q8h po.                             Cefoperazone Sodium i.v.                         None                      None                                              None
  3                          Arbidol 0.2 g q8h po.                             Moxifloxacin i.v.                                Methylprednisolone i.v.   High-flow nasal cannula, mechanical ventilation   High-flow nasal cannula
  4                          Ribavirin 0.5 g qd i.v.                           Linezolid i.v.Imipenem-Sitastatin Sodium i.v.    Methylprednisolone i.v.   Mechanical ventilation                            High-flow nasal cannula
  5                          Arbidol 0.2 g q8h po.                             Moxifloxacin i.v.                                Methylprednisolone i.v.   Low-flow nasal cannula                            Low-flow nasal cannula
  Remdesivir 0.2 g qd i.v.   Cefoperagone Sodium and Tazobactam Sodium i.v.                                                                                                                                 
  IFN-ɑ 500MIU qd inh.                                                                                                                                                                                      
  6                          Arbidol 0.2 g q8h po.                             Cefoperazone Sodium i.v.Levofloxacin i.v.        Methylprednisolone i.v.   High-flow nasal cannula                           High-flow nasal cannula
  7                          Arbidol 0.2 g q8h po.                             Cefoperagone Sodium and Tazobactam Sodium i.v.   Methylprednisolone i.v.   High-flow nasal cannula                           None
                             Fluconazole i.v.                                                                                                                                                               
  8                          Arbidol 0.2 g q8h po.                             None                                             None                      None                                              None
  Ribavirin 0.5 g qd i.v.                                                                                                                                                                                   
  9                          Arbidol 0.2 g q8h po.Oseltamivir 75 mg q12h po.   None                                             None                      Low-flow nasal cannula                            Low-flow nasal cannula (Intermittent)
  Peramivir 0.3 g qd i.v.                                                                                                                                                                                   
  10                         Arbidol 0.2 g q8h po.IFN-ɑ 500 MIU qd inh.        Cefoperazone Sodium i.v.Caspofungin i.v.         Methylprednisolone i.v.   High-flow nasal cannula                           High-flow nasal cannula

po., per os; i.v., i.v. injection; inh., inhalation; q8h, every 8 h; qd, per day; q12h, every 12 h; MIU, million IU.

On computer-assisted tomography (CT), all patients presented bilateral ground-glass opacity and/or pulmonary parenchymal consolidation with predominantly subpleural and bronchovascular bundles distribution in the lungs. Seven patients had multiple lobe involvement, and four patients had interlobular septal thickening.

Effects of CP Transfusion. {#s4}
--------------------------

### Improvement of clinical symptoms. {#s5}

All symptoms in the 10 patients, especially fever, cough, shortness of breath, and chest pain, disappeared or largely improved within 1 d to 3 d upon CP transfusion. Prior to CP treatment, three patients received mechanical ventilation, three received high-flow nasal cannula oxygenation, and two received conventional low-flow nasal cannula oxygenation. After treatment with CP, two patients were weaned from mechanical ventilation to high-flow nasal cannula, and one patient discontinued high-flow nasal cannula. Besides, in one patient treated with conventional nasal cannula oxygenation, continuous oxygenation was shifted to intermittent oxygenation ([Table 2](#t02){ref-type="table"}).

### Reduction of pulmonary lesions on chest CT examinations. {#s6}

According to chest CTs, all patients showed different degrees of absorption of pulmonary lesions after CP transfusion. Representative chest CT images of patient 9 and patient 10 are shown on [Fig. 1](#fig01){ref-type="fig"}. Patient 9, a 49-y-old female admitted 1 day postonset of illness (dpoi), showed the most obvious pulmonary image improvement. At 10 dpoi, one dose of 200-mL transfusion of CP was given. The SARS-CoV-2 RNA converted to negative at 12 dpoi. Compared with the result at 7 dpoi, massive infiltration and ground-glass attenuation disappeared on CT image performed at 13 dpoi, accompanied by a much better pulmonary function. Patient 10, a 50-y-old male, was admitted 3 dpoi and was given a 200-mL transfusion of CP at 20 dpoi. His chest CT presented massive infiltration and widespread ground-glass attenuation on admission and started to show a gradual absorption of lung lesions 5 d after CP transfusion. The SARS-CoV-2 RNA became negative at 25 dpoi.

![Chest CTs of two patients. (*A*) Chest CT of patient 9 obtained on February 9 (7 dpoi) before CP transfusion (10 dpoi) showed ground-glass opacity with uneven density involving the multilobal segments of both lungs. The heart shadow outline was not clear. The lesion was close to the pleura. (*B*) CT Image of patient 9 taken on February 15 (13 dpoi) showed the absorption of bilateral ground-glass opacity after CP transfusion. (*C*) Chest CT of patient 10 was obtained on February 8 (19 dpoi) before CP transfusion (20 dpoi). The brightness of both lungs was diffusely decreased, and multiple shadows of high density in both lungs were observed. (*D*) Chest CT of patient 10 on February 18 (29 dpoi) showed those lesions improved after CP transfusion.](pnas.2004168117fig01){#fig01}

### Amelioration of routine laboratory criteria and pulmonary function. {#s7}

Lymphocytopenia, an important index for prognosis in COVID-19 ([@r2]), tended to be improved after CP transfusion (median: 0.65 × 10^9^ per L vs. 0.76 × 10^9^ per L), 7 out of 10 patients showing an increase of lymphocyte counts ([Fig. 2](#fig02){ref-type="fig"}). Concerning other laboratory tests, we observed a tendency of decrement of parameters indicative of inflammation and/or liver dysfunction as compared to the status before CP therapy. These included C-reactive protein (CRP) (median: 55.98 mg/L vs. 18.13 mg/L), alanine aminotransferase (median: 42.00 U/L vs. 34.30 U/L), and aspartate aminotransferase (median: 38.10 U/L vs. 30.30 U/L) ([Table 3](#t03){ref-type="table"}). The total bilirubin (median: 12.40 μmol/L vs. 13.98 μmol/L) remained unchanged, except for an obvious increment in patient 1 ([Fig. 2](#fig02){ref-type="fig"}). An increase of SaO~2~ (median: 93.00% vs. 96.00%), a measurement constantly performed in most patients in our trial, was found, which could indicate recovering lung function. This temporal relationship was notable despite the provision of maximal supportive care and antiviral agents.

![Dynamic changes of laboratory parameters in all patients. The dotted horizontal line represents the reference value range. SaO~2~, oxyhemoglobin saturation; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Lym, lymphocyte.](pnas.2004168117fig02){#fig02}

###### 

Comparison of laboratory parameters before and after CP transfusion

  Clinical factors                                          Before CP transfusion    After CP transfusion
  --------------------------------------------------------- ------------------------ ------------------------
  CRP (mg/L, normal range 0 to 6)                           55.98 (15.57 to 66.67)   18.13 (10.92 to 71.44)
  Lymphocyte (10^9^ per L, normal range 1.1 to 3.2)         0.65 (0.53 to 0.90)      0.76 (0.52 to 1.43)
  Alanine aminotransferase (U/L, normal range 9 to 50)      42.00 (28.25 to 61.85)   34.30 (25.75 to 53.90)
  Aspartate aminotransferase (U/L, normal range 15 to 40)   38.10 (28.50 to 44.00)   30.30 (17.30 to 38.10)
  Total bilirubin (μmol/L, normal range 0 to 26)            12.40 (11.71 to 22.05)   13.98 (12.20 to 20.80)
  SaO~2~ (%, normal range ≥ 95)                             93.00 (89.00 to 96.50)   96.00 (95.00 to 96.50)

SaO~2~, oxyhemoglobin saturation.

Remarkably, patient 1, a 46-y-old male admitted 8 dpoi, had a very quick recovery, with much improved result of laboratory tests. He received antiviral drugs (arbidol and ribavirin) treatment and high-flow nasal cannula on admission. Mechanical ventilation was given at 10 dpoi for critical care support. CP transfusion was performed at 11 dpoi. At 12 dpoi, the SARS-CoV-2 test turned to negative, with a sharp decrease of CRP from 65.04 mg/L to 23.57 mg/L and increment of SaO~2~ from 86% to 90% ([Fig. 3](#fig03){ref-type="fig"}). The mechanical ventilation was successfully weaned off 2 d after CP transfusion. At 15 dpoi, a steady elevation of lymphocyte count and a drop of aminopherase level were observed, indicating improvement of immunological and hepatic function.

![Change of laboratory parameters in patient 1. The *x* axis represents the day post-CP transfusion. The dotted horizontal line represents the reference value range.](pnas.2004168117fig03){#fig03}

### Increase of neutralizing antibody titers and disappearance of SARS-CoV-2 RNA. {#s8}

We determined neutralizing antibody titers before and after CP transfusion in all patients except one (patient 2) ([Table 4](#t04){ref-type="table"}). The neutralizing antibody titers of five patients increased and four patients remained at the same level after CP transfusion. SARS-CoV-2 RNA, assayed by RT-PCR, was positive in seven patients and negative in three cases before CP transfusion. Of note is that SARS-CoV-2 RNA was decreased to an undetectable level in three patients on day 2, three patients on day 3, and one patient on day 6 after CP therapy. These results are in support of a neutralizing effect of CP on serum SARS-CoV-2.

###### 

Comparison of serum neutralizing antibody titers and SARS-CoV-2 RNA load before and after CP therapy

  Patient no.   CP transfusion date   Before CP transfusion   After CP transfusion                                          
  ------------- --------------------- ----------------------- ---------------------- ---------- ------------- ------------- ----------
  1             February 9            February 8              1:160                  37.25      February 10   1:640         Negative
  2             February 9            February 8              Unavailable            35.08      February 11   Unavailable   Negative
  3             February 13           February 12             1:320                  38.07      February 14   1:640         Negative
  4             February 13           February 12             1:160                  37.68      February 14   1:640         Negative
  5             February 12           February 11             1:640                  Negative   February 14   1:640         Negative
  6             February 12           February 11             1:640                  Negative   February 14   1:640         Negative
  7             February 12           February 11             1:320                  34.64      February 14   1:640         Negative
  8             February 12           February 11             1:640                  35.45      February 14   1:640         Negative
  9             February 12           February 11             1:160                  Negative   February 14   1:640         Negative
  10            February 9            February 8              1:640                  38.19      February 14   1:640         Negative

### Outcome of patients treated with CP as compared to a recent historic control group. {#s9}

A historic control group was formed by random selection of 10 patients from the cohort treated in the same hospitals and matched by age, gender, and severity of the diseases to the 10 cases in our trial. Baseline characteristics of patients between CP treatment group and control group showed no significant differences, while clinical outcomes of these two groups were different: three cases discharged while seven cases in much improved status and ready for discharge in CP group, as compared to three deaths, six cases in stabilized status, and one case in improvement in the control group (*P* \< 0.001; [*SI Appendix*, Table S1](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2004168117/-/DCSupplemental)).

Adverse Effects of CP Transfusions. {#s10}
-----------------------------------

Patient 2 showed an evanescent facial red spot. No serious adverse reactions or safety events were recorded after CP transfusion.

Discussion {#s11}
==========

Our study explores the feasibility of CP therapy in COVID-19. All enrolled severe COVID-19 patients achieved primary and secondary outcomes. One dose of 200-mL CP transfusion was well tolerated, while the clinical symptoms significantly improved with the increase of oxyhemoglobin saturation within 3 d, accompanied by rapid neutralization of viremia.

Severe pneumonia caused by human coronavirus was characterized by rapid viral replication, massive inflammatory cell infiltration, and elevated proinflammatory cytokines or even cytokine storm in alveoli of lungs, resulting in acute pulmonary injury and acute respiratory distress syndrome (ARDS) ([@r17]). Recent studies on COVID-19 demonstrated that the lymphocyte counts in the peripheral blood were remarkably decreased and the levels of cytokines in the plasma from patients requiring intensive care unit (ICU) support, including IL-6, IL-10, TNF-ɑ, and granulocyte-macrophage colony-stimulating factor, were significantly higher than in those who did not require ICU conditions ([@r2], [@r18]). CP, obtained from recovered COVID-19 patients who had established humoral immunity against the virus, contains a large quantity of neutralizing antibodies capable of neutralizing SARS-CoV-2 and eradicating the pathogen from blood circulation and pulmonary tissues ([@r19]). In the present study, all investigated patients achieved serum SARS-CoV-2 RNA negativity after CP transfusion, accompanied by an increase of oxygen saturation and lymphocyte counts, and the improvement of liver function and CRP. The results suggest that the inflammation and overreaction of the immune system were alleviated by antibodies contained in CP. The case fatality rates (CFRs) in the present study were 0% (0/10), which was comparable to the CFRs in SARS, which varied from 0% (0/10) to 12.5% (10/80) in four noncomparative studies using CP treatment ([@r9], [@r20][@r21]--[@r22]). Based on our preliminary results, CP therapy can be an easily accessible, promising, and safe rescue option for severe COVID-19 patients. It is, nevertheless, worth mentioning that the absorption of pulmonary lesions often lagged behind the improvement of clinical symptoms, as shown in patients 9 and 10 in this trial.

The first key factor associated with CP therapy is the neutralizing antibody titer. A small sample study in MERS-CoV infection showed that the neutralizing antibody titer should exceed 1:80 to achieve effective CP therapy ([@r12]). To find eligible donors who have high levels of neutralizing antibody is a prerequisite. Cao et al. ([@r23]) showed that the level of specific neutralizing antibody to SARS-CoV decreased gradually 4 mo after the disease process, reaching undetectable levels in 25.6% (IgG) and 16.1% (neutralizing antibodies) of patients at 36 mo after disease status. A study from the MERS-CoV−infected patients and the exposed healthcare workers showed that the prevalence of MERS-CoV IgG seroreactivity was very low (2.7%), and the antibodies titer decreased rapidly within 3 mo ([@r24]). These studies suggested that the neutralizing antibodies represented short-lasting humoral immune response, and plasma from recently recovered patients should be more effective. In the present study, recently recovered COVID-19 patients, who were infected by SARS-CoV-2 with neutralizing antibody titer above 1:640 and recruited from local hospitals, should be considered as suitable donors. The median age of donors was lower than that of recipients (42.0 y vs. 52.5 y). Among the nine cases investigated, the neutralizing antibody titers of five patients increased to 1:640 within 2 d, while four patients kept the same level. The antibody titers in CP in COVID-19 seem thus higher than those used in the treatment of MERS patient (1:80) ([@r12]).

The second key factor associated with efficacy is the treatment time point. A better treatment outcome was observed among SARS patients who were given CP before 14 dpoi (58.3% vs. 15.6%; *P* \< 0.01), highlighting the importance of timely rescue therapy ([@r9]). The mean time from onset of illness to CP transfusion was 16.5 d. Consistent with previous research, all three patients receiving plasma transfusion given before 14 dpoi (patients 1, 2, and 9) in our study showed a rapid increase of lymphocyte counts and a decrease of CRP, with remarkable absorption of lung lesions in CT. Notably, patients who received CP transfusion after 14 dpoi showed much less significant improvement, such as patient 10. However, the dynamics of the viremia of SARS-CoV-2 was unclear, so the optimal transfusion time point needs to be determined in the future.

In the present study, no severe adverse effects were observed. One of the risks of plasma transfusion is the transmission of the potential pathogen. Methylene blue photochemistry was applied in this study to inactivate the potential residual virus and to maintain the activity of neutralizing antibodies as much as possible, a method known to be much better than ultraviolet (UV) C light ([@r25]). No specific virus was detected before transfusion. Transfusion-related acute lung injury was reported in an Ebola virus disease woman who received CP therapy ([@r26]). Although uncommon in the general population receiving plasma transfusion, this specific adverse reaction is worth noting, especially among critically ill patients experiencing significant pulmonary injury ([@r27]). Another rare risk worth mentioning during CP therapy is antibody-dependent infection enhancement, occurring at subneutralizing concentrations, which could suppress innate antiviral systems and thus could allow logarithmic intracellular growth of the virus ([@r28]). The special infection enhancement also could be found in SARS-CoV infection in vitro ([@r29]). No such pulmonary injury and infection enhancement were observed in our patients, probably owing to high levels of neutralizing antibodies, timely transfusion, and appropriate plasma volume.

There were some limitations to the present study. First, except for CP transfusion, the patients received other standard care. All patients received antiviral treatment despite the uncertainty of the efficacy of drugs used. As a result, the possibility that these antiviral agents could contribute to the recovery of patients, or synergize with the therapeutic effect of CP, could not be ruled out. Furthermore, some patients received glucocorticoid therapy, which might interfere with immune response and delay virus clearance. Second, the median time from onset of symptoms to CP transfusion was 16.5 d (IQR, 11.0 d to 19.3 d). Although the kinetics of viremia during natural history remains unclear, the relationship between SARS-CoV-2 RNA reduction and CP therapy, as well as the optimal concentration of neutralizing antibodies and treatment schedule, should be further clarified. Third, the dynamic changes of cytokines during treatment were not investigated. Nevertheless, the preliminary results of this trial seem promising, justifying a randomized controlled clinical trial in a larger patient cohort.

In conclusion, this pilot study on CP therapy shows a potential therapeutic effect and low risk in the treatment of severe COVID-19 patients. One dose of CP with a high concentration of neutralizing antibodies can rapidly reduce the viral load and tends to improve clinical outcomes. The optimal dose and treatment time point, as well as the definite clinical benefits of CP therapy, need to be further investigated in randomized clinical studies.

Materials and Methods {#s12}
=====================

Patients. {#s13}
---------

From January 23, 2020, to February 19, 2020, 10 patients in three participating hospitals (Wuhan Jinyintan Hospital; the Jiangxia District Hospital of Integrative Traditional Chinese and Western Medicine, Wuhan; and the First People's Hospital of Jiangxia District, Wuhan) were recruited in this pilot study. All patients were diagnosed as having severe COVID-19 according to the WHO Interim Guidance ([@r30]) and the Guideline of Diagnosis and Treatment of COVID-19 of National Health Commission of China (version 5.0) ([@r31]), with confirmation by real-time RT-PCR assay. The enrollment criteria were one of the conditions 2 to 4 plus condition 1: 1) age ≥ 18 y; 2) respiratory distress, RR ≥30 beats/min; 3) oxygen saturation level less than 93% in resting state; and 4) partial pressure of oxygen (PaO~2~)/oxygen concentration (FiO~2~) ≤ 300 mmHg (1 mmHg = 0.133 kPa). The exclusion criteria were as follows: 1) previous allergic history to plasma or ingredients (sodium citrate); 2) cases with serious general conditions, such as severe organ dysfunction, who were not suitable for CP transfusion. Written informed consent according to the Declaration of Helsinki was obtained from each patient or legal relatives. This study was approved by the Ethics Committee of the China National Biotec Group Co., Ltd. (Approval number 2020-0001). The registration number of this trial is ChiCTR2000030046.

Donors for Convalescent Plasma Transfusion. {#s14}
-------------------------------------------

Ten donor patients who recovered from COVID-19 were recruited from three participating hospitals. The recovery criteria were as follows: 1) normality of body temperature for more than 3 d, 2) resolution of respiratory tract symptoms, and 3) two consecutively negative results of sputum SARS-CoV-2 by RT-PCR assay (1-d sampling interval). The donor's blood was collected after 3 wk postonset of illness and 4 d postdischarge. Written informed consent was obtained from each patient.

Plasma Preparation Procedure and Quality Control. {#s15}
-------------------------------------------------

Apheresis was performed using a Baxter CS 300 cell separator (Baxter). Convalescence plasma for treatment was collected from 40 donors. The median age was 42.0 y (IQR, 32.5 y to 49 y). A 200- to 400-mL ABO-compatible plasma sample was harvested from each donor depending on age and body weight, and each sample was divided and stored as 200-mL aliquots at 4 °C without any detergent or heat treatment. The CP was then treated with methylene blue and light treatment for 30 min in the medical plasma virus inactivation cabinet (Shandong Zhongbaokang Medical Appliance Co., Ltd).

Serology Test and Real-Time RT-PCR Detection of SARS-CoV-2 and Other Pathogens. {#s16}
-------------------------------------------------------------------------------

The neutralizing activity of plasma was determined by plaque reduction neutralization test using SARS-CoV-2 virus in the high biosafe level (BSL-4) laboratory of Wuhan Institute of Virology, Chinese Academy of Sciences. Neutralization titer was defined as the highest serum dilution with 50% reduction in the number of plaques, as compared with the number of plaques in wells in the absence of novel coronavirus antibody as blank control. The neutralizing activity of the receptor-binding domain of antibody in the CP was detected by a sandwich enzyme-linked immunosorbent assay (ELISA). SARS-CoV-2 IgG antibody titer was tested by ELISA. SARS-CoV-2 RNA was detected by RT-PCR assay, and the result was presented as cycle threshold (Ct) value (Shanghai BioGerm Medical Biotechnology Co., Ltd). Methylene blue residue was detected by the verified UV method. The serology screening for hepatitis B and C virus, HIV, and syphilis spirochete was negative. The protocols for neutralization assay, serological test, and real-time RT-PCR detection of SARS-CoV RNA are presented in [*SI Appendix*](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2004168117/-/DCSupplemental).

Treatment. {#s17}
----------

All patients were admitted to the ICU and received antiviral therapy and other supportive care, while some patients received antibiotic treatment, antifungal treatment, glucocorticoid, and oxygen support at the appropriate situation. One dose of 200 mL of inactivated CP with neutralization activity of \>1:640 was transfused into the patients within 4 h following the WHO blood transfusion protocol.

Data Collection. {#s18}
----------------

Clinical information of all enrolled patients was retrieved from the hospital electronic history system, including the baseline demographic data, days of illness duration, presenting symptoms, different kinds of examination, and methods of treatment. Bacterial coinfection was identified by a positive culture from respiratory, urinary, or blood culture within 48 h of hospital admission. Complications, including acute renal failure, acute coronary syndrome, myocarditis, ARDS, and nosocomial infection, were recorded. The applications of assisted mechanical ventilation, intranasal oxygen inhalation, and medication regimen were recorded. The SARS-CoV-2 RNA from the serum sample was monitored during treatment.

Outcome Measures and Definitions. {#s19}
---------------------------------

The clinical symptoms were recorded by attending physicians daily. The blood test and biochemical tests were carried out every 1 d to 2 d. SARS-CoV-2 RNA was detected every 2 d to 3 d. CT scan was repeated every 3 d to 5 d. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory and radiological parameters within 3 d after CP transfusion. Clinical symptoms improvement was defined as temperature normalization, relief of dyspnea, and oxygen saturation normalization, and radiological improvement was defined as different degrees of absorption of lung lesions.

Statistical Analysis. {#s20}
---------------------

Continuous variables were presented as the median and IQR. Graphs were plotted using GraphPad Prism 7.0. Statistical software used included SPSS 24.0.

Data Availability Statement. {#s21}
----------------------------

All data relevant to this manuscript and available to the authors at the time of publication are included in the main text or [*SI Appendix*](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2004168117/-/DCSupplemental). Further detailed data on patients that support the findings of this study have been deposited in the Open Science Framework (<https://osf.io/gahz5>).
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